LSC-2

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameLSC-2
Drug Alias NameABCB5+ limbal stem cellsLSC-2
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Limbal stem cell therapy
Mechanisms of ActionStem cell replacements
TargetsUpdating
Therapy Area/IndicationsLimbal Stem Cell DeficiencyCorneal Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRheacell
China Registration ClassN/A

Develop Information

Active CompaniesTiceba GmbhRheacellRheacell Gmbh & Co Kg
Inactive CompaniesN/A
Active IndicationsLimbal Stem Cell DeficiencyCorneal Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A